211 related articles for article (PubMed ID: 18580862)
21. Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma.
Walcher D; Hess K; Heinz P; Petscher K; Vasic D; Kintscher U; Clemenz M; Hartge M; Raps K; Hombach V; Marx N
Hypertension; 2008 Feb; 51(2):259-66. PubMed ID: 18158351
[TBL] [Abstract][Full Text] [Related]
22. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system.
Kurtz TW; Pravenec M
J Hypertens; 2004 Dec; 22(12):2253-61. PubMed ID: 15614015
[TBL] [Abstract][Full Text] [Related]
23. The ONTARGET/TRANSCEND Trial Programme: baseline data.
Sleight P
Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
[TBL] [Abstract][Full Text] [Related]
24. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
Yamagishi S; Takenaka K; Inoue H
Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710
[TBL] [Abstract][Full Text] [Related]
25. Rationale for double renin-angiotensin-aldosterone system blockade.
Unger T; Stoppelhaar M
Am J Cardiol; 2007 Aug; 100(3A):25J-31J. PubMed ID: 17666194
[TBL] [Abstract][Full Text] [Related]
26. Telmisartan and cardioprotection.
Akhrass PR; McFarlane SI
Vasc Health Risk Manag; 2011; 7():677-83. PubMed ID: 22140319
[TBL] [Abstract][Full Text] [Related]
27. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.
Benndorf RA; Rudolph T; Appel D; Schwedhelm E; Maas R; Schulze F; Silberhorn E; Böger RH
Metabolism; 2006 Sep; 55(9):1159-64. PubMed ID: 16919533
[TBL] [Abstract][Full Text] [Related]
28. Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.
Scalera F; Martens-Lobenhoffer J; Bukowska A; Lendeckel U; Täger M; Bode-Böger SM
Hypertension; 2008 Mar; 51(3):696-703. PubMed ID: 18250362
[TBL] [Abstract][Full Text] [Related]
29. A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones.
Tagami T; Yamamoto H; Moriyama K; Sawai K; Usui T; Shimatsu A; Naruse M
Endocrinology; 2009 Feb; 150(2):862-70. PubMed ID: 19147680
[TBL] [Abstract][Full Text] [Related]
30. Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ by core hopping of telmisartan.
Zhang J; Liu X; Wang SQ; Liu GY; Xu WR; Cheng XC; Wang RL
J Biomol Struct Dyn; 2017 Sep; 35(12):2665-2680. PubMed ID: 27602589
[TBL] [Abstract][Full Text] [Related]
31. Renin-angiotensin system blockade and cardiovascular and renal protection.
Hoogwerf BJ
Am J Cardiol; 2010 Jan; 105(1 Suppl):30A-5A. PubMed ID: 20102971
[TBL] [Abstract][Full Text] [Related]
32. Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND).
Böhm M; Baumhäkel M; Probstfield JL; Schmieder R; Yusuf S; Zhao F; Koon T;
Am Heart J; 2007 Jul; 154(1):94-101. PubMed ID: 17584560
[TBL] [Abstract][Full Text] [Related]
33. Focus on the ONTARGET results.
Elliott HL
J Hypertens Suppl; 2009 Jun; 27(2):S8-S10. PubMed ID: 19491625
[TBL] [Abstract][Full Text] [Related]
34. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
[TBL] [Abstract][Full Text] [Related]
35. Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients.
Vecchiet J; Ucciferri C; Falasca K; Mancino P; Di Iorio A; De Caterina R
Antivir Ther; 2011; 16(5):639-45. PubMed ID: 21817185
[TBL] [Abstract][Full Text] [Related]
36. Telmisartan modulates mitochondrial function in vascular smooth muscle cells.
Takeuchi K; Yamamoto K; Ohishi M; Takeshita H; Hongyo K; Kawai T; Takeda M; Kamide K; Kurtz TW; Rakugi H
Hypertens Res; 2013 May; 36(5):433-9. PubMed ID: 23254392
[TBL] [Abstract][Full Text] [Related]
37. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.
Toyama K; Nakamura T; Kataoka K; Yasuda O; Fukuda M; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
Biochem Biophys Res Commun; 2011 Jul; 410(3):508-13. PubMed ID: 21679694
[TBL] [Abstract][Full Text] [Related]
38. Telmisartan prevents angiotensin II-induced endothelial dysfunction in rabbit aorta via activating HGF/Met system and PPARγ pathway.
Hu ZP; Fang XL; Qian HY; Fang N; Wang BN; Wang Y
Fundam Clin Pharmacol; 2014 Oct; 28(5):501-11. PubMed ID: 24188213
[TBL] [Abstract][Full Text] [Related]
39. Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation.
Younis F; Stern N; Limor R; Oron Y; Zangen S; Rosenthal T
Metabolism; 2010 Aug; 59(8):1200-9. PubMed ID: 20070992
[TBL] [Abstract][Full Text] [Related]
40. Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice.
Blessing E; Preusch M; Kranzhöfer R; Kinscherf R; Marx N; Rosenfeld ME; Isermann B; Weber CM; Kreuzer J; Gräfe J; Katus HA; Bea F
Atherosclerosis; 2008 Aug; 199(2):295-303. PubMed ID: 18093593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
